Xiang “Shawn” Zhang was named director of the Lester and Sue Smith Breast Center at Baylor College of Medicine after serving as interim director since March 2022.
MDsave has begun its annual campaign to reduce the cost of 2D and 3D screening mammograms.
Results from a collaborative study on universal hereditary cancer genetic testing in all patients with breast cancer in a rural population in the Annals of Surgical Oncology. Conducted by Invitae in collaboration with The Outer Banks Hospital in North Carolina from 2019 to 2022, the study analyzed the implementation of universal hereditary cancer genetic testing in all patients with breast cancer, as recommended by the American Society of Breast Surgeons guidelines in 2019.
MD Anderson Cancer Center has established the Texas Health Equity Alliance for Breast Cancer (THEAL), a community-wide health care initiative to reduce breast cancer disparities in the Houston area, particularly for Black women.
Montefiore Einstein Comprehensive Cancer Center opened a breast center at the Hutchinson Metro Center at 1250 Waters Place.
City of Hope is initiating a multicenter clinical trial to evaluate the efficacy of robotic-assisted, single-incision mastectomies.
Oncologist Kaitlyn O’Keefe has joined Oncology Specialists of Charlotte.
Jack Cuzick will receive the William L. McGuire Memorial Lecture Award at the 2023 San Antonio Breast Cancer Symposium Dec. 5-9 at the Henry B. Gonzalez Convention Center in San Antonio.
Mehran Habibi was named director of breast surgery for Staten Island University Hospital and chief of breast surgery for Northwell Health system’s Western Region, which includes Staten Island, Manhattan, and Westchester County. He will also serve as director of international program development for the Northwell Cancer Institute.
Patient-reported outcomes data from the phase III NATALEE trial, presented at the European Society for Medical Oncology Virtual Plenary, show that a broad population of patients with stage 2 and 3 hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer maintained health-related quality of life during treatment with Kisqali (ribociclib) plus endocrine therapy.
